$8.87
+0.37 (+4.35%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where KYTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 observational
Held by 12 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, +7 more) · FINRA short interest 8.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101NCT07403188observationalNumber of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | — | Recruiting | Drug: KYV-101 | Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc) | 70 | Jan 2041 | ≤ 5,278 d | 2026-02-11 |
| KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisNCT06342960Incidence adverse events (AEs) and laboratory abnormalities (Phase 1 and Phase 2)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: KYV-101 anti-CD19 CAR-T cell therapy · Drug: Standard lymphodepletion regimen | Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | 2 | Oct 2028 | ≤ 803 d | 2025-10-29 |
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisNCT06193889Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2)Randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Standard of Care Treatment, Standard lymphodepletion regimen · Biological: KYV-101 | Myasthenia Gravis, Generalized Myasthenia Gravis | 66 | Sep 2027 | ≤ 406 d | 2026-07-29 |
| KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNCT06384976To evaluate efficacy of KYV-101Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Biological: KYV-101 · Drug: Standard lymphodepletion regimen, Anti-CD20 mAB | Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS | 120 | Apr 2027 | ≤ 253 d | 2025-01-13 |
| KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus NephritisNCT05938725Incidence adverse events (AEs) and laboratory abnormalities (Phase 1 and Phase 2)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: KYV-101 anti-CD19 CAR-T cell therapy · Drug: Standard lymphodepletion regimen | Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV | 6 | Aug 2026 | ≤ 11 d | 2025-10-29 |
| KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic SclerosisNCT06400303Incidence of adverse events and laboratory abnormalities (Phase 1)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: KYV-101 · Drug: Standard lymphodepletion regimen | Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria | 3 | Mar 2026 | — | 2025-10-08 |
| KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person SyndromeNCT06588491To evaluate efficacy of KYV-101Open-label · Treatment | Phase 2 | Completed | Biological: Standard lymphodepletion regimen | Stiff-Person Syndrome, SPS | 27 | 2026-06-25actual | — | 2026-07-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19